(Q37721614)

22 August 2017

1 reference

title

Towards evidence-based treatment of thrombotic antiphospholipid syndrome (English)

1 reference

22 August 2017

author

Ronald H. W. M. Derksen

series ordinal

1

object named as

R H W M Derksen

1 reference

22 August 2017

P G de Groot

2

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

19

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

470-474

1 reference

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Management of antiphospholipid antibody syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

How I treat the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Counci

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

Thrombophilia, clinical factors, and recurrent venous thrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309361483

21 January 2018

Identifiers

DOI

10.1177/0961203309361483

1 reference

22 August 2017

1 reference